Ancient herbs meet modern medicine: can Curcumin-QingDai tame UC?
NCT ID NCT07665294
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether adding a combination of curcumin (from turmeric) and QingDai (a traditional Chinese herb) to standard vedolizumab treatment can help people with moderate to severe ulcerative colitis reach remission. About 160 adults will receive either the herbal combo or a placebo, alongside their usual vedolizumab. The main goal is to see if more people achieve symptom-free remission after 12 weeks.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Curcumin-QingDai (CurQD) capsules
What this could lead to
If it works, this could point toward a safe, plant-based add-on therapy to help more people with ulcerative colitis achieve remission without stronger drugs.
What could go wrong
This is a relatively small Phase 4 trial testing a supplement combination, so results may not be definitive. The placebo effect in UC trials is often high, and QingDai has been linked to rare but serious lung and liver issues.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ULCERATIVE COLITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Icahn School of Medicine at Mount Sinai
New York, New York, 10029, United States